Halaven

Cancer Drugs Fund ( CDF ) Panel has assessed the application for Eribulin ( Halaven ) to remain in the CDF...



Data from a pooled analysis presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (...


Halaven ( Eribulin mesylate ), a non-taxane, microtubule dynamics inhibitor with a novel mechanism of action, belongs to a class...


The results of a phase III study ( Study 301 ) of Eribulin mesylate ( Halaven ) versus Capecitabine (...